616875-90-2

Basic information

• Product Name: TERT-BUTYL OCTAHYDRO-1,6-NAPHTHYRIDINE-6(7H)-CARBOXYLATE
• Synonyms: TERT-BUTYL OCTAHYDRO-1,6-NAPHTHYRIDINE-6(7H)-CARBOXYLATE
• CAS NO: 616875-90-2
• Molecular Formula: C13H24N2O2
• Molecular Weight: 240.34
• Mol File: 616875-90-2.mol

Chemical Properties

• Boiling Point: 331.7°C at 760 mmHg
• Flash Point: 154.4°C
• Appearance: /
• Density: 1.032g/cm³
• Vapor Pressure: 0.000153mmHg at 25°C
• Refractive Index: 1.484
• CAS DataBase Reference: TERT-BUTYL OCTAHYDRO-1,6-NAPHTHYRIDINE-6(7H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL OCTAHYDRO-1,6-NAPHTHYRIDINE-6(7H)-CARBOXYLATE(616875-90-2)
• EPA Substance Registry System: TERT-BUTYL OCTAHYDRO-1,6-NAPHTHYRIDINE-6(7H)-CARBOXYLATE(616875-90-2)

Safety Data

• Hazardous Substances Data: 616875-90-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H24N2O2/c1-13(2,3)17-12(16)15-8-6-11-10(9-15)5-4-7-14-11/h10-11,14H,4-9H2,1-3H3

Upstream product

• 259809-44-4 7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Relevant articles and documents

Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold

A series of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold were identified with good cellular and human whole blood activity against IDO1. These inhibitors contain multiple chiral centers and all diastereomers were separated. The absolute stereochemistry of each isomers were not determined. Compounds 15 and 27 stood out as leads due to their good cellular as well as human whole blood IDO1 inhibition activity, low unbound clearance, and reasonable mean residence time in rat cassette PK studies.

ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.